Purchase Today online Kadcyla Trastuzumab Emtansine 160mg Injection for GlobMedIndia - The Medicine Exporter India - Nagpur, Mumbai, Delhi, Rajasthan, Kerala, Uttar Pradesh, Pune, Gujarat, Surat.

Kadcyla Trastuzumab Emtansine 160mg Injection

Kadcyla (Trastuzumab Emtansine) 160mg Injection is a targeted anti-cancer medication used primarily for the treatment of HER2-positive metastatic breast cancer. It is a combination of a monoclonal antibody (trastuzumab) and a cytotoxic agent (emtansine), designed to deliver chemotherapy directly to HER2-positive cancer cells while minimizing exposure to healthy cells. This makes it highly effective in controlling tumor growth with fewer systemic side effects compared to traditional chemotherapy.

Contact Details to Place Order:

💬 WhatsApp: +91 9730316395
📞 Phone: +91 9730316395
📧 Email: info@globmedindia.com
🌐 Website: https://globmedindia.com

Composition and Content

Trastuzumab – a monoclonal antibody that targets the HER2 receptor on cancer cells.
Emtansine (DM1) – a cytotoxic agent linked to trastuzumab for targeted chemotherapy.
Excipients – includes stabilizers, buffers, and other components to maintain solution integrity.
Dosage Form – 160 mg per vial as a sterile, lyophilized powder for intravenous infusion.

How to Use & Dosage

Administration: Intravenous infusion under medical supervision.
Recommended Dose: Typically 3.6 mg/kg body weight every 3 weeks, but dosage may be adjusted based on patient condition and tolerance.
Infusion Time: Usually over 30–90 minutes, depending on tolerance.
Precautions: Pre-medication may be required to prevent infusion-related reactions. Patients should be monitored for cardiac function and liver health.

Uses and Treatments

Primary use in HER2-positive metastatic breast cancer patients who previously received trastuzumab and a taxane.
Helps in slowing cancer progression, reducing tumor size, and improving survival rates.
Often used as part of a comprehensive treatment plan including surgery, radiotherapy, or other chemotherapies.

Advantages

Targeted therapy reduces systemic side effects.
Combines the efficacy of trastuzumab with the cytotoxic effect of emtansine.
Convenient dosing schedule (every 3 weeks).
Improves progression-free survival in HER2-positive breast cancer patients.

Storage Conditions

Store 2°C–8°C (refrigerated).
Protect from light.
Do not freeze.
Use immediately after reconstitution or follow recommended storage after dilution.

Alternative Indian Brands

T-DM1 Biocon – India-based biosimilar option.
Kadtraz – alternative by Indian pharmaceutical companies for trastuzumab emtansine.
Trastemax – another locally manufactured biosimilar.

(Availability may vary; consult your oncologist for suitability.)